Canaccord Genuity Sticks to Their Buy Rating for Harbour Energy (HBR)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Sharp is a 5-star analyst with an average return of 24.5% and a 53.21% success rate. Sharp covers the Energy sector, focusing on stocks such as Arrow Exploration Corp, Vaalco Energy, and Nostrum Oil & Gas.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Harbour Energy with a p254.00 average price target.
The company has a one-year high of p316.37 and a one-year low of p146.40. Currently, Harbour Energy has an average volume of 2.91M.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HBR in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Canaccord Trims Elastic (ESTC) Price Target, Maintains Buy
Elastic N.V. (NYSE:ESTC) is one of the best SaaS stocks to buy according to analysts. Canaccord Genuity trimmed its price target on Elastic N.V. (NYSE:ESTC) to $110 from $115 while maintaining a Buy rating, following what it described as a solid fourth-quarter performance. The firm noted Elastic delivered better-than-expected results on both revenue and earnings, underscoring operational discipline and demand resilience despite a mixed macro environment. A group of software engineers working in an open, futuristic office. Notably, Canaccord pointed out that while total revenue exceeded estimates, the composition of that beat leaned more heavily on Elastic's self-managed offerings than on its cloud-native platform, Elastic Cloud. Cloud growth, a key long-term focus for the company, came in slightly below expectations, suggesting some variability in adoption pace or customer expansion. Still, the firm emphasized that Elastic's guidance for the coming quarters appears 'amply conservative,' leaving room for the company to outperform its own targets. With cost management measures in place and increasing enterprise interest in search-powered AI tools, Canaccord believes Elastic is positioned to exceed expectations over the course of the year. Shares of Elastic have rebounded in recent months as investor confidence has strengthened around the company's ability to execute a balanced growth strategy. The lowered target reflects a more cautious near-term stance but doesn't change the firm's broader view that Elastic remains an attractive play in the search and observability space. While we acknowledge the potential of ESTC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None.
Yahoo
8 hours ago
- Yahoo
Sagtec Global (NASDAQ SAGT) Achieves Key Milestone in UAE Smart Hospitality Deal; On Track for 2025 Revenue Recognition
KUALA LUMPUR, Malaysia, July 25, 2025 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT) ('Sagtec' or the 'Company'), a provider of enterprise software solutions for high-growth verticals, today announced the successful delivery of the first phase of its previously disclosed US$10 million smart hospitality contract in the United Arab Emirates (UAE), in partnership with SMD Tech – FZCO. The Company has received the first milestone payment, validating both project execution and commercial delivery. The deal, originally announced in July 2025, is structured with over 60% of total value as multi-year recurring revenue, covering software licensing, analytics, hosting, and long-term service. The project remains on schedule for full delivery in 2025, with corresponding revenue capture anticipated within the current fiscal year. 'This milestone represents more than operational progress—it reinforces our ability to monetize large-scale SaaS contracts, generate recurring cash flow, and expand strategically in a high-growth international market,' said Kevin Ng, Chairman, Executive Director & CEO of Sagtec Global. 'It reflects our disciplined execution and strong regional partnerships.' Momentum Across Vertical SaaS Offerings In addition to progress in the UAE, Sagtec confirms that its Speed+ Smart Ordering System, which supports a US$30 million pipeline across Southeast Asia, has now been successfully deployed to commercial end-users. Speed+ is a cloud-based solution tailored for the F&B and hospitality industries, designed to improve service efficiency and increase revenue per transaction. These dual deployments reinforce Sagtec's strategy to scale vertically integrated SaaS platforms across multiple industries—hospitality, F&B, and smart infrastructure—with a strong focus on monetizable outcomes. 'We are executing on multiple fronts with clear revenue visibility,' added Ng. 'These wins strengthen our position ahead of our next earnings cycle and demonstrate the scalability of our recurring revenue model.' Well-Positioned in a US$30B+ Market With the UAE hospitality sector forecasted to reach US$37.7 billion by 2033 (IMARC Group), Sagtec's expansion into the Middle East positions the Company at the center of a regional transformation toward smart tourism and digital-first guest experiences. Backed by a resilient balance sheet and growing recurring revenue base, Sagtec remains focused on margin-accretive growth, product innovation, and geographic expansion to drive long-term shareholder value. About Sagtec Global Limited Sagtec Global is a technology company delivering customizable software solutions to the hospitality, F&B, and enterprise sectors. The Company also operates digital infrastructure businesses, data hosting & analysis services through its Malaysian Subsidiary, CL Technologies. For more information on the Company, please log on to Contact Information: Sagtec Global Limited Contact:Ng Chen LokChairman, Executive Director & Chief Executive Officer Telephone +6011-6217 3661 Email: info@
Yahoo
10 hours ago
- Yahoo
Piper Sandler Says These 2 Stocks Are Top Picks for the Second Half of 2025
There's no magic formula for picking winning stocks, but having the right guide can make all the difference. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That's where Wall Street's analysts come in. With a front-row seat to market movements and company performance, these pros make it their business to spot standout opportunities. And now, with 2025 beyond the halfway mark, it's the perfect moment to check in on the names they're backing for the rest of the year. Watching the current mid-year situation for Piper Sandler, analyst Jason Bednar lays out the attributes he's looking for in top-pick stocks, writing: 'Key themes across our top names include confidence we have in management's execution against guidance and Street estimates for the coming quarters, balance sheet flexibility that is good and/or improving, and risk/reward that skews favorably based on a combination of catalysts and valuation on shares.' With this in mind, we dug into the TipRanks database to get the broader Wall Street take on two of his top picks, and both are rated Buy, with the potential for double-digit gains. Let's break down the names, the numbers, and what makes them stand out. STERIS (STE) First up on our list, STERIS, is a medical technology (medtech) company. STERIS was founded in 1985 and is based in Ohio; the company got its start specializing in low-temperature liquid sterilization of surgical instruments. Today, the company is a global leader in infection prevention, offering a line of products and services designed to support patient care for a better medical outcome. To achieve that goal, STERIS offers a diverse array of products, including medical consumables such as detergents, endoscopy accessories, and barrier devices. On the service side, the company can install and maintain medical equipment, provide sterilization for medical devices, repair medical instruments and scopes, and provide lab testing. Finally, STERIS can also provide its customers with larger-scale capital equipment, such as surgical tables, automated endoscope reprocessors, and even integrated connectivity solutions for today's high-tech operating rooms. STERIS offers its products under several categories, and reports its revenue under the categories Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The largest of these is Healthcare, which accounted for approximately 73% of the company's total revenue in its last reported quarter. That quarter was fiscal 4Q25 (March quarter), for which STERIS reported $1.5 billion in total revenue. This was up 4% year-over-year and beat the forecast by $30 million. At the bottom line, STERIS realized a quarterly adjusted net income of $2.74 per diluted share, a figure that was 14 cents above expectations. The company's free cash flow rose year-over-year, from $620.3 million to $787.2 million in the current report. Checking in with Piper Sandler, we find that analyst Bednar wastes no time in explaining why this stock made his list. Bednar writes, 'Why is it a top idea? STE is a model of consistency, posting MSD+ top-line and HSD/LDD bottom-line growth in six of the past seven years, underpinned by healthy end markets, disciplined capital allocation and a focus on lean operations. For medtech investors, that's a model deserving of a premium valuation. Growth in the high-margin AST segment has improved sequentially for six consecutive quarters, and the segment growth outlook has gotten cleaner of late… Balance sheet leverage is as light as it's been in several years (~1.3x net leverage), and this Board/mgmt team have a bias to accretive M&A.' Based on this stance, Bednar rates STE shares as Overweight (i.e., Buy), with a $280 price target to suggest a one-year upside potential of 24%. (To watch Bednar's track record, click here) The consensus rating here is a Moderate Buy, based on 5 Buy and 2 Hold ratings. Meanwhile, the $270.33 average target price indicates room for an upside of 20% by this time next year. (See STE stock forecast) Merit Medical Systems (MMSI) The second stock we're looking at here is another medtech, Merit Medical Systems. This firm, based in the suburbs of Salt Lake City, Utah, is known as a developer, manufacturer, and distributor of medical devices, particularly devices used in interventional, diagnostic, and therapeutic procedures. Merit Medical's product lines feature proprietary designs, and are intended to be disposable; they are most often used in the fields of cardiology, radiology, oncology, critical care, and endoscopy. Merit Medical has a global footprint, with some 7,300 employees, including an international team of marketers and clinical support that totals more than 800. The company is recognized as a global leader in disposable medical tools. The company boasts a market cap of $5 billion. Earlier this month, Merit suffered a sharp blow to its stock price, falling as much as 10% on July 16, after a regulatory disclosure. That disclosure involved a warning letter from the FDA, regarding issues of quality control at one of the company's manufacturing facilities. These types of warnings are not uncommon from regulators, but in this case, the timing is a problem – Merit is currently expanding its product lines, and a warning letter of this type may have a stronger impact than usual. The company has already stated that it is working in concert with the FDA to address the issues raised in the letter. Looking at Merit's product lines, we find that the company has its hands in a wide range of categories. To give a small list: the company produces hemostasis accessories, dialysis equipment, safety kits, infusion systems, pulmonary stents, GI dilation balloons, and blood sampling devices. The company also provides educational resources, including on-demand courses and recorded webinars, to provide tutorials on its various equipment lines and products. We can also note that on May 6 this year, Merit announced its latest regulatory approval, with Health Canada's approval of Merit's Wrapsody Cell-Impermeable Endoprosthesis. The company is also undergoing a leadership change, and current CEO Fred Lampropoulos will be stepping down in October. His place will be taken by Martha Aronson, effective on October 3. Mr. Lampropoulos will remain as Chairman of the Board. Merit's last quarterly report covered 1Q25, and in that quarter the company had revenues of $355.4 million. This was up 10% year-over-year and beat the forecast by $2.8 million. The non-GAAP EPS figure, of 86 cents, beat expectations by 11 cents per share. Checking in again with Piper Sandler's Bednar, we see the analyst weighing various pros and cons here, writing, 'MMSI has demonstrated durable and consistent growth and management has been superb in managing investor expectations over the past 4+ years… Management already positively pre-announced 2Q and detailed CEO transitions plans, but we also see an EPS beat and guidance raise as being in order. The WRAPSODY reimbursement strategy will be a focal point after failing to secure TPT on management's previously announced timeline, but we're optimistic the developments to date will result in this being more of a short delay for securing TPT.' Summing up, Bednar sees this medtech as a solid choice, and advises investors to buy in, saying of MMSI, 'Longer-term, we believe an extension of what's been a solid execution story should keep MMSI one of the premium mid-cap assets in medtech.' These comments are complemented by an Overweight (i.e., Buy) rating, and a price target which, at $110, points toward a one-year gain of 29%. This stock has earned a Strong Buy from the Street's analysts, a consensus based on 10 recent reviews that split 9 to 1 in favor of Buy over Hold. The shares are currently trading for $85.06 and the average price target of $108.80 implies the stock will gain 28% in the next 12 months. (See MMSI stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
